Recombinant Human Keratinocyte Growth Factor in Unrelated and Related Transplants

Safety and Efficacy of Recombinant Human Keratinocyte Growth Factor in Unrelated and Related Transplants

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00056875

Enrollment

Registered

2003-03-27

Start date

2002-09-30

Completion date

2005-06-30

Last updated

2015-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Graft Versus Host Disease

Keywords

graft versus host disease, bone marrow transplant, alternative donor

Brief summary

This is a single arm dose escalation study of recombinant human keratinocyte growth factor given to patients undergoing allogeneic bone marrow transplantation who are at high risk for graft versus host disease (GVHD).

Detailed description

Completion date provided represents the completion date of the grant per OOPD records

Interventions

DRUGrecombinant human keratinocyte growth factor

Study design

Allocation

NON_RANDOMIZED

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

3 Years to 65 Years

Healthy volunteers

Inclusion criteria

Eligible for full intensity bone marrow transplant (BMT) conditioning but who lack a 6/6 HLA idential sibling donor

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026